Phase II open label, multi‐center clinical trial of modulation of intermediate endpoint biomarkers by 1α‐hydroxyvitamin D2 in patients with clinically localized prostate cancer and high grade pin

Prostate cancer is the most common malignancy and second leading cause of cancer related deaths in American men supporting the study of prostate cancer chemoprevention. Major risk factors for this disease have been associated with low serum levels of vitamin D. Here, we evaluate the biologic activity of a less calcemic vitamin D analog 1α‐hydroxyvitamin D2 [1α‐OH‐D2] (Bone Care International, Inc.) in patients with prostate cancer and high grade prostatic intraepithelial neoplasia (HG PIN).

[1]  D. Tindall,et al.  Effect of dutasteride on the risk of prostate cancer. , 2010, The New England journal of medicine.

[2]  H. DeLuca,et al.  Mechanisms and functions of vitamin D. , 2009, Nutrition reviews.

[3]  D. Albanes,et al.  Family history of prostate cancer and prostate cancer risk in the Alpha‐Tocopherol, Beta‐Carotene Cancer Prevention (ATBC) Study , 2008, International journal of cancer.

[4]  Nilanjan Chatterjee,et al.  Serum vitamin D concentration and prostate cancer risk: a nested case-control study. , 2008, Journal of the National Cancer Institute.

[5]  D. McNeel,et al.  Randomized, Double-Blinded Phase II Evaluation of Docetaxel with or without Doxercalciferol in Patients with Metastatic, Androgen-Independent Prostate Cancer , 2008, Clinical Cancer Research.

[6]  Yan Liu,et al.  Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. , 2006, Journal of the National Cancer Institute.

[7]  Ruth Etzioni,et al.  Associations of demographic and lifestyle characteristics with prostate‐specific antigen (PSA) concentration and rate of PSA increase , 2006, Cancer.

[8]  L. Rodríguez-Mañas,et al.  Seasonal Variance in Serum Levels of Vitamin D Determines a Compensatory Response by Parathyroid Hormone: Study in an Ambulatory Elderly Population in Quebec , 2006, Gerontology.

[9]  Zuxiong Chen,et al.  Preferential production of latent transforming growth factor β‐2 by primary prostatic epithelial cells and its activation by prostate‐specific antigen , 2005, Journal of cellular physiology.

[10]  V. Adhami,et al.  Oral Consumption of Green Tea Polyphenols Inhibits Insulin-Like Growth Factor-I–Induced Signaling in an Autochthonous Mouse Model of Prostate Cancer , 2004, Cancer Research.

[11]  A. Gudkov,et al.  Secreted transforming growth factor β2 activates NF-κB, blocks apoptosis, and is essential for the survival of some tumor cells , 2004 .

[12]  Michael M Lieber,et al.  The influence of finasteride on the development of prostate cancer. , 2003, The New England journal of medicine.

[13]  H. Parnes,et al.  The Future of Prostate Cancer Prevention , 2001, Annals of the New York Academy of Sciences.

[14]  R. Lieberman.  Prostate cancer chemoprevention: Strategies for designing efficient clinical trials. , 2001, Urology.

[15]  M. Hakama,et al.  Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland) , 2000, Cancer Causes & Control.

[16]  G. Siegal,et al.  1 alpha,25-Dihydroxyvitamin D (calcitriol) inhibits the invasiveness of human prostate cancer cells. , 1997, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[17]  D. Feldman.  Androgen and vitamin D receptor gene polymorphisms: the long and short of prostate cancer risk. , 1997, Journal of the National Cancer Institute.

[18]  G. Coetzee,et al.  Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. , 1997, Journal of the National Cancer Institute.

[19]  J. Mohler,et al.  Association of prostate cancer with vitamin D receptor gene polymorphism. , 1996, Cancer research.

[20]  G. Miller,et al.  Stable expression of the nuclear vitamin D receptor in the human prostatic carcinoma cell line JCA-1: evidence that the antiproliferative effects of 1 alpha, 25-dihydroxyvitamin D3 are mediated exclusively through the genomic signaling pathway. , 1996, Endocrinology.

[21]  D. Bostwick,et al.  Prostatic intraepithelial neoplasia is a risk factor for adenocarcinoma: predictive accuracy in needle biopsies. , 1995, The Journal of urology.

[22]  E. Corder,et al.  Seasonal variation in vitamin D, vitamin D-binding protein, and dehydroepiandrosterone: risk of prostate cancer in black and white men. , 1995, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[23]  P. Lipponen,et al.  Nuclear morphometry is of independent prognostic value only in T1 prostatic adenocarcinomas , 1995, The Prostate.

[24]  R. Marks,et al.  The effect of regular sunscreen use on vitamin D levels in an Australian population. Results of a randomized controlled trial. , 1995, Archives of dermatology.

[25]  D. Peehl,et al.  Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. , 1993, Endocrinology.

[26]  M. Lucia,et al.  The human prostatic carcinoma cell line LNCaP expresses biologically active, specific receptors for 1 alpha,25-dihydroxyvitamin D3. , 1992, Cancer research.

[27]  R. Mason,et al.  Stability of vitamin D metabolites in human blood serum and plasma. , 1981, Clinical chemistry.

[28]  A. Jemal,et al.  Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.

[29]  Pär Stattin,et al.  Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: A longitudinal, nested case‐control study in the Nordic countries , 2004, International journal of cancer.

[30]  John H. White,et al.  The pleiotropic actions of vitamin D. , 2004, BioEssays : news and reviews in molecular, cellular and developmental biology.

[31]  G. Stark,et al.  Secreted transforming growth factor beta2 activates NF-kappaB, blocks apoptosis, and is essential for the survival of some tumor cells. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[32]  D. Peehl,et al.  Actions of vitamin D3, analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3. , 1995, Endocrinology.

[33]  B. Hulka,et al.  Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis). , 1990, Anticancer research.

[34]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.